No Data
No Data
Express News | Acrivion Therapeutics Shares Are Trading Higher After the Company Announced It Will Present Data From Its Analysis of ACR-2316
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, Its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
12 Health Care Stocks Moving In Wednesday's Intraday Session
Acrivon Therapeutics Reports Progress in Cancer Drug Development
Press Release: Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer